Comparison of 18F-RO948, 18F-MK6240, and 18F-GTP1 in Alzheimer Disease and Older Controls

Phase 1, randomised, open-label trial of [18F]RO-948, florquinitau and [18F]GTP1 in Alzheimer's disease (AD) (3 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Amyloid positivity of patients with Alzheimer disease or positive memory or thinking problem CDR assessment compared to amyloid negative older healthy controls, Imaging capability of 18F-RO948, 18F-MK6240 and 18F-GTP1 in patients with Alzheimer disease or positive memory or thinking problem CDR assessment, and amyloid negative older healthy controls, as… and 1 more. Started Feb 2023; status: active, not recruiting.